LambdaFabSelect is for the purification of antibody fragments containing a lambda light chain
GE Healthcare Life Sciences has added a new affinity resin to its portfolio of technologies for the purification of antibody-based fragments, following collaboration with BAC NV, a provider of antibody-based affinity purification technology based in The Netherlands.
The LambdaFabSelect resin is a tool for the GMP-regulated purification of antibodies and antibody fragments that contain a lambda light chain. Antibody fragments are said to have a number of advantages over monoclonal antibodies, such as improved tissue penetration and the ability to bind to targets inaccessible to conventional antigen-binding sites.
The two firms have previously collaborated on the development of the KappaSelect affinity resin, which is for the purification of antibodies and antibody fragments containing the kappa light chain.
GE Healthcare Life Sciences’ director of custom design media, Henrik Ihre, said: ‘One of the key challenges in antibody and antibody fragment purification is to design resins that are highly selective and can cover a broad range of different antibody formats. Collaborating with the team at BAC has resulted in a ready-to-use product for all human antibody formats containing a lambda light chain.’
LambdaFabSelect enables bioprocess engineers to use BAC’s ligand technology to produce Fab fragments with a lambda light chain for clinical and commercial use. It is said to provide greater flexibility in the purification of these biotherapeutics.
BAC was established in 1995 as a Unilever subsidiary. The firm employs 37 people and has an r&d laboratory in Leiden and an ISO 9001 certified manufacturing plant in Naarden.